Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
|Murugan Avaniyapuram Kannan|
|King Faisal Specialist Hospital & Research Center, KSA|
|ScientificTracks Abstracts: J Blood Disord Transfus|
|PI3Ks are heterodimeric lipid kinases that regulate cellular activities such as proliferation, survival, motility and morphology through the second messenger PIP3. Studies have reported that the P110α (PIK3CA), the catalytic subunit of PI3-kinase is somatically mutated in human cancers. Here, we found PIK3CA mutations in 29.4% of head and neck squamous cell carcinoma cell lines, 10.5% of Indian, 11.7% of Japanese (unpublished data) and no mutation in Vietnamese tumors. Functional analysis of these mutations including a novel insertion mutation in Indian tumor showed increased PI3 kinase activities, followed by growth factor-independent proliferation, changes in morphology, a higher rate of cell migration and invasion. Our findings suggest that PIK3CA mutations in HNSCC are likely to be oncogenic and may significantly contribute to HNSCC carcinogenesis and pave an attractive target for therapeutic prevention. As there were no mutations found in PIK3CA of Vietnamese oral cancers, we hypothesized that the RAS could be more likely activated as an upstream effector of PI3K. We, therefore, sequenced the exons 1 and 2 of H-RAS. The RAS mutations were detected in 10 of 56 tumors (18%) suggesting that RAS is an important member in the PI3K/Akt signaling and could play an important role in the tumorigenesis of oral carcinoma. SWAP-70 is a PIP3 binding protein involved in actin rearrangement, especially in membrane ruffling. Mouse embryo fibroblast (MEFs) deficient in SWAP-70 show impaired membrane ruffling and fail to grow on soft agar after transformation by v-Src. Here, we show that MEFs transformed by v-Src-expressing SWAP-70 are highly invasive. MEFs expressing SWAP-70 or v-Src alone were far less invasive, suggesting that both proteins were required for the cells to be invasive.|
Murugan Avaniyapuram Kannan completed his PhD from the Department of Molecular Oncology, Tokyo Medical and Dental University, Tokyo, Japan and Postdoctoral studies from Hoshi University, Tokyo, Japan and The Johns Hopkins University School of Medicine, Baltimore, USA. Currently, he is a Scientist in the Department of Molecular Oncology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia. He has published more than 35 papers in reputed journals and holds a patent for identification of novel ALK mutations in anaplastic thyroid cancer. His research focuses on molecular biology of head and neck squamous cell carcinoma and thyroid cancer identifying molecular therapeutic targets and biomarkers. He has been serving as Reviewer in Thyroid, PLOS One, Oncogene, Cancer Research, Tumor Biology, Endocrine Related Cancer, Oral Oncology, etc.
|PDF | HTML|